George Magrath bought $98k of IRD
Chief Executive Officer at Opus Genetics, Inc.. 100,000 shares at an average of $0.98, traded Dec 26, 2024, filed Dec 30, 2024.
Score components
- +25RoleCEO
- +10Trade size$98k at market
- +6Relative to holdingsHoldings up 20%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000905148-24-003425, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 26, 2024 | POpen-market purchase Common Stock | +100,000 | $0.98 | $98k | 599,150 | Dec 30, 2024 |
Related signals
Other insiders at Opus Genetics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | IRDsell Opus Genetics, Inc. | Foundation Fighting Blindness Retinal Degeneration Fund director, other | $2.8M 556,000 shares | -15% | |
| 13Weak | Opus Genetics, Inc. | Robert E. Gagnon Chief Financial Officer | $127k 28,000 shares | -5% | |
| 36Weak | IRDbuy Opus Genetics, Inc. | Cam Gallagher director | $324k 164,000 shares | +9% | |
| 50Moderate | IRDsell Opus Genetics, Inc. | Foundation Fighting Blindness Retinal Degeneration Fund director, other | $8.6M 4,000,000 shares | -42% | |
| 28Weak | Opus Genetics, Inc. | Benjamin R Yerxa President | $9,834 10,000 shares | +3% | |
| 49Moderate | Opus Genetics, Inc. | George Magrath Chief Executive Officer | $101k 100,000 shares | +25% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.